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Summary
We previously showed that fibronectin (FN) synergized with anti-CD3 in induction ofCD4+
T cell proliferation, and that VLA-5 acted as a functional FN receptor in a serum-free culture
system . In the present study, we showed that VLA-4 is also involved in this CD3-dependent
CD4 cell activation through its interaction with the alternatively spliced CS1 domain of FN .
When highly purified CD4 cells were cultured on plates coated with anti-CD3 plus synthetic
CS1 peptide-IgG conjugate, significant proliferation could be observed . Neither CS1 alone nor
anti-CD3 alone induced this activation. This proliferation was completely blocked by antiVLA01
(4134) and anti-VLA-4 (8F2), while antiVLA5 (monoclonal antibody [mAb] 16 and 2H6) had
no effect . These data indicate that VLA-4 mediates CD3-dependent CD4 cell proliferation via
the CS1 domain of FN . AntiVLA-4 also partially (10-40%) inhibited CD4 cell proliferation
induced by native FN plus anti-CD3, implying that the CS1 domain is active in the native plasma
FN . However, this native FN-dependent proliferation was entirely abolished by addition of anti-
VLA-5 alone. Moreover, when native FN-coated plates were pretreated with anti-FN (mAb 333),
which blocks RGDS sites but not CS1 sites, no CD4 cell activation could be observed. These
results strongly suggest thatCD4 cell activation induced by plasma FN/anti-CD3 may be dependent
on bothVLA4/CS1 and VLA5/RGDS interactions, although the latter interaction may be required
for function of the former.
I
t is now evident that CD4+ T cells can be divided into
two distinct functional subsets based upon their expres-
sion of different isoforms of the leukocyte common an-
tigens/T200 family (CD45/CD45RA) (1-3) and theCD29
(4134) antigen (4) . CD4+CD45RA- CD29+(CD29high) cells
provide strong helper function for B cell Ig production, re-
spond maximally to recall antigens (4), and induce CD8 cells
to exert class I-restricted cytotoxicity (5) . The CD4+
CD45RA+CD29 -(CD291°W) cells, in contrast, can induce
CD8 cells to suppress Ig synthesis but provide poor helper
function, and respond poorly to recall antigens . The CD29
(4134) antigen has been shown to belong to the VLA/inte-
grin super gene family (6) . These transmembrane glycopro-
teins are expressed on a variety of cell types including lym-
phocytes. The VLA protein family consists of acommon /31
subunit noncovalently associated with different a chains to
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form different heterodimers (7, 8) . At least six VLA proteins
have been identified based on their distinct a chains . Most
of these VLA proteins are known to function as cell surface
receptors for extracellular matrix proteins, including fibro-
nectin, collagen, and laminin . Thus, they are considered to
play a significant role in a variety of biological processes, in-
cluding cell migration, embryogenesis, and tumor metastasis
(7, 8) . However, their function in theimmune system is largely
unknown . WhileCD29 expression correlates with the func-
tion of subsets ofCD4 cells, the mechanism underlying this
relationship is still unclear.
Our recent observation (9) that fibronectin (FN)t syner-
gizes with the CD3/TCR pathway to promote CD4+ T
1 Abbreviations used in this paper . FN, fibronectin ; SPDP, N-succinimidyl-
3(2-pyridylithio) propionate.
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mechanism by which extracellular matrix proteins modulate
immune function . When plasmaFN is crosslinked with anti-
CD3 on culture plates, highly purified CD4cells were max-
imally activated in a serum-free culture system . This anti-
CD3/FN-dependent proliferation was specifically inhibited
by anti-4B4 (anti-VLA-a1) and antiVLA5 antibodies, sug-
gesting that VLA-5 was acting as a major functional FN
receptor in our system . It has subsequently been demonstrated
that VLA-4 also functions as another type of FN receptor
(10-12). While thebinding ofVLA-5 is mediated by an Arg-
Gly-Asp-Ser (RGDS)-containing cell binding domain in the
central portion ofFN (13, 14), that ofVLA-4 to FN is medi-
ated by an alternatively spliceddomain (CS1) of the FN mol-
ecule (10) . Since CS1 is different from RGDS in its sequence
(10, 15, 16), the FN molecule has at least two distinct cell
bindingdomains. In contrast to otherVLA proteins, which
are distributed widely on a variety of cell types, the expres-
sion of VLA-4 is relatively restricted to myeloid and lym-
phoid cells (7). It is therefore conceivable that VLA-4 might
have a significant role inT cell function through its interac-
tion with FN . We now present evidence that immobilized
syntheticCS1peptides, via their interaction with the VLA-4
receptor, provide a signal synergistic with anti-CD3 in
promotingCD4 cell proliferation . Moreover, we demonstrate
that CD4cell proliferation inducedby anti-CD3 plus native
plasmaFN is dependent on bothVLA-4 andVLA5, although
the latter may be required for full function of the former.
Materials and Methods
Reagents . Human FN was obtained from Collaborative Re-
search, Lexington, MA . BSA, transferrin, and soybean lipids used
in the serum-free medium were from Boehringer Mannheim Bio-
chemicals, Mannheim, FRG . IMDM was from Sigma Chemical
Co ., St . Louis, MO.
Antibodies.
￿
mAbs reactive with the lymphocyte surface antigens,
CD3 (RW24B6, IgG2b ; OKT3, IgG2a),CD8 (21Thy-2D3, IgG1),
CD11a (2F12, IgG1), CD11b(Mol, IgM), CD29 (4B4, IgG1), have
been described previously (4, 17-19) . Anti-8F2 is reactive with the
a4 subunit of VLA (antiVLA-4), and has been described previ-
ously (9) . mAb 16 is an IgG2a of rat origin and recognizes the
ot5 VLA subunit(antiVLA-5) (9) . Anti-2116antibody (IgG1) was
developed in our laboratoryby standard hybridoma techniques after
immunization of a mouse with the K562 cell line . It was deter-
mined that anti-2116 reacted with the VLA-5 protein as follows.
The protein immunoprecipitated by anti-2116had thesame molec-
ular weight as that immunoprecipitated by themAb 16 antibody.
Moreover, sequential immunoprecipitation studies showed that both
antibodies reacted with thesame molecule (data notshown) . mAb
333 is a rat anti-humanFN antibody and was characterized previ-
ously (20) . This antibody binds close to the RGDS sequence of
the FN molecule and blocks its function .
Preparation of CS1 Peptides .
￿
The alternatively spliced CS1 do-
main of the type III connecting segment (IIICS) of human FN,
as well as truncated and scrambled homologues, were prepared as
described previously (15, 16) . Fig. 1 shows theamino acid sequences
oftheCS1 peptide and related peptides used in our study. According
to an adhesion assay using melanoma cell lines, theLDVtripeptide
is the most important region for the promotion of adhesion by
CS1(Komoriya et al ., manuscript in preparation) . CS1-DandCS1-A,
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as well as the original CS1 peptide, contain this sequence, and there-
fore exhibit cell attachment capabilities . Their relative activity, as
determined by themelanoma cell adhesion assay, is CS1 > CSI-D
> CS1-A. In contrast, CS1-B and CS1-scrl do not contain theLDV
tripeptide, and therefore have no adhesive activity. They are used
as negative controls in our study. It should be noted that CS1-scrl
is identical to CS1 except in its final eightamino acids (Fig. 1, un-
derlined), which are scrambled such that no amino acid retains its
original position . ForT cell adhesion and proliferation assays, CSl
peptides were covalently coupled to rabbit IgGusing heterobifunc-
tional crosslinker N-succinimidyl-3(2-pyridyldithio) propionate
(SPDP), as described elsewhere (15, 16) In brief, SPDP was dis-
solved in ethanol at a concentration of 1.5 mg/ml andmixed with
6 mg/ml rabbit IgG (Miles Scientific, Naperville, IL) in Dulbecco's
PBS to give an SPDP/IgG weight ratio of 1:10 (molar ratio of50:1) .
After30 min of incubation at room temperature, unreacted SPDP
wasremovedby gel filtration on a PD-10 column (Pharmacia Fine
Chemicals, Piscataway, NJ) equilibrated with PBS . The activated
IgGwasthen added to CS1 peptide at a peptide/IgG weight ratio
of0.3-0.45 . Aftermixing overnighton a rotator at room tempera-
ture, free peptide was removed by dialysis against PBS . To deter-
mine theamount of CS1 in the conjugate, [3H]CSI peptides were
used as a carrier, as described previously (16) . The number of pep-
tide molecules/IgG molecule was found to be -15 for each CS1-
IgG conjugate.
Preparation of Cells.
￿
Human PBL were isolated from healthy
donors as described previously (9) . Briefly, the lymphocytes were
separated into erythrocyte rosette-positive (T cells) and -negative
populations with sheep erythrocytes . The T cells were depleted
of contaminating monocytes by adherence to plastic plates . Fur-
ther removal of monocytes from T cells was achieved by incuba-
tion with 5 MM t-leucine methyl ester HCI. CD4` T cells were
obtained by incubating T cells with anti-CD8, anti-CD11b, and
L243, and panningon anti-Ig-coated petri dishes to remove residual
monocytes . TheCD4 cells thus obtained were >90% CD4', with
<5% contamination by CD8' cells . The contamination by mono-
cytes was <1 in 500 cells as determined by peroxidase staining .
Cell Culture andProliferation Assays.
￿
For preparation of micro-
titer plates coated with anti-CD3 plus CSI-IgG or anti-CD3 plus
FN, 100P .1 of protein A-purified anti-CD3 antibody at 0.1 hg/ml
in PBS was plated in each well of a 96-well flat-bottomed plate
(3595 ; Costar, Cambridge, MA), which was then incubated for
3 h at room temperature. After washing twice with PBS, 100 P1
of PBS containing the indicated amounts of CS1-IgGor FN were
then plated in each well and incubated for 3 h at room tempera-
ture . Before use, wells were washed three times with PBS. T cells
were cultured in triplicate wells at a concentration of 105 cells/well
in serum-free medium consisting of Iscove's MEM supplemented
with 0.1% BSA, 30P.g/ml human transferrin, 10 ug/ml soybean
lipids, 50 wg/ml cholesterol, 4MM. L-glutamine, 25 mM Hepes
buffer (Microbiological Associates, Bethesda, MD), 0.5% sodium
CS1 CDELPQLVTLPHPNLHGPEILDVPST
CSI-D CVTLPHPNLHGPEB.DVPST
CS I-A EILDVPST
CSI-B CDELPQLVTL
CSI-Scrl CDELPQLVTLPHPNLHGPPVTSELID
Figure 1 .
￿
Amino acid sequence of CSl and its related peptides. CSl
contains residues 1-25 ofthe type III connecting segment ofFN, and com-
prises an entire spliced segment . CSI-scrl was designed to have the same
sequence as CSl, except for the underlined segment in which eight amino
acids were scrambled such that no amino acid retained its original position .bicarbonate, and 50 lAg/ml of gentamicin sulfate (Schering, Kenil-
worth, NJ) . After 4 d in culture, each well was labeled with
1 1ACi of [3H]thymidine (ICN Radiochemicals, Irvine, CA) for
18 h . Cells were then harvested on a PHD cell harvester (Cam-
bridge Technology, Inc., Cambridge, MA), and [3H]thymidine in-
corporation was measured with a (3 scintillation counter. For anti-
body inhibition assays, cells were preincubated with media
containing various amounts ofantibodies for 30 min at room tem-
perature before being added to the ligand-coated wells in the con-
tinued presence of the antibodies.
Cell Adhesion Assay.
￿
Cell adhesion assays were performed ac-
cording to the method of Yamada and Kennedy (21) with minor
modifications . In brief, 96-well microtiter plates were incubated
with 100 Al of CS1-IgG conjugate for 3 h at room temperature,
followed by incubation with heat-treated BSA (10 min at 80°C)
in PBS (5 mg/ml) for 2 h at room temperature and washing with
PBS . Jurkat cells were labeled with ['H]thymidine for 6 h before
the adhesion assay, and were then plated on CS1-IgG-coated plates,
and incubated for i h at 37°C . The unbound cells were removed
by washing with PBS. The bound cells were lysed with 2% SDS
and 0.1% NaOH, and the radioactivity in the cell lysates was ana-
lyzed using a iB scintillation counter.
Results
CSI Peptides Synergize with Anti-CD3 to Promote CD4+ T
Cell Proliferation. Our previous study (9) demonstrated that
CD4 cells were activated when they were cultured on plates
coated with both anti-CD3 and FN in a serum-free culture
medium . Moreover, VLA5 was shown to operate as a func-
tional FN receptor in this system . However, recent evidence
has indicated that VLA4 acts as a lymphocyte receptor for
the alternatively spliced CS1 domain of plasma FN (10, 11) .
To determine whether this CS1 domain of plasma FN can
also provide a complementary signal with anti-CD3 in the
activation ofCD4 cells, we studied the effect of the synthetic
CSI peptide on the proliferation of highly purifiedCD4 cells
in a serum-free culture system .
As shown in Fig. 2, no proliferation above background
was observedwhen CD4 cells were cultured with anti-CD3
antibody alone or CS1 peptide conjugate alone. In contrast,
when CD4 cells were cultured on plates coated with both
anti-CD3 and CS1, marked proliferation was observed . The
control peptide, CS1-scrl, had no effect, even when combined
Figure 2.
￿
Comitogenic effect of
CSI peptide on CD3-dependent
CD4 cellproliferation . CD4 cells
were cultured on plates coated
with anti-CD3 (0 .1 Ftg/ml), CS1
(2 .5 nmol/ml), or CS1-scrl (2.5
nmol/ml), alone or in combina-
tion . After4 d ofculture, prolifer-
ation was assessed by determining
[3H]thytnidine incorporation . The
data are expressed as the mean of
triplicate samples. Each SD was
<15%. The data shown are rep=
resentative of five separate ex-
periments.
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Figure 3 .
￿
Soluble CS1 peptide
inhibits the proliferation induced
by anti-CD3 plus immobilized
CS1 peptide .CD4 T cells were in-
cubated with various concentra-
tions of soluble CS1 or CSI-scrl
peptides for 30 min, and then
placed onto culture plates coated
with anti-CD3 (,0 .1 ug/ml) and
CS1 peptide (0 .5 mnol/ml) . After
4 d, proliferation was assessed by
determination of [3H]thymidine
incorporation . The data are ex-
pressed as the mean of triplicate
samples . Each SD was <15% . The
data shown are representative of
Amount ofPeptWe (4mq
￿
three separate experiments .
with anti-CD3 . These results indicate that the combination
of CS1 peptide and anti-CD3 is a potent activator for CD4
cells . As shown in Fig. 3, the addition of soluble CS1 pep-
tide to the culture medium resulted in inhibition of CD4
cell proliferation induced by anti-CD3 plus CS1, in a dose-
dependent fashion . The control peptide, CS1-scrl, did not
have any effect . These results suggest that the interaction of
CS1 and its receptor may be important in the CD4 cell acti-
vation observed .
Anti-4B4 (Anti-VLA01)andAnti-8F2 (Anti-VLAci4) Inhibit
Anti-CD3/CS1-Dependent CD4 Cell Proliferation . Cell adhe-
sion assays (10-12, 15, 16) have recently provided convincing
evidence that the CS1 domain of the FN molecule recog-
nizes the VLA-4 protein. Therefore, we next examined
whether the proliferative response ofCD4 cells in our system
was also mediated by aCS1/VLA4 interaction, by performing
an antibody inhibition study. As shown in Fig . 4, anti-VLA
X31 (anti-4114) and antiVLA-4 (anti-8F2) antibodies almost
completely inhibited the proliferation ofCD4 cells activated
by anti-CD3 plus CS1. In contrast, neither anti-VLA5 (anti-
2H6 or mAb 16) antibodies nor anti-LFAI (anti-2F12) anti-
body (isotype control, IgG1) had any effect at concentrations
up to 10 Ag/ml . Likewise, antibodies against otherVLA family
antigens (VLA 1, 2, 3, and 6) did not inhibit anti-CD3 plus
CS1-mediated CD4 cell proliferation (data not shown) . On
the other hand, anti-4114 and anti-8F2 antibodies failed to
inhibit T cell proliferation induced by the combination of
anti T112 and anti T113 (data not shown) . These results sug-
gested that the interaction of CS1 and VLA-4 is specifically
involved in CD4 cell activation induced by anti-CD3 plus CS1.
CS1 PromotesJurkat T Cell Adhesion, Which Is Specifically
Blocked by Anti-4B4 andAnti-8F2 Antibodies. The above study
implied that anti-4114 and anti-8F2 might inhibitT cell acti-
vation by blocking the binding of CS1 peptides to their
receptor (VLA4) onCD4 cells . To confirm this, we performed
cell binding studies utilizing CS1- or FN-coated plates . How-
ever, probably due to poor binding of freshly isolatedT cells
to such plates, appreciable binding of CD4 cells could not
be observed . Therefore, we performed cell adhesion assays
using the Jurkat T cell line, which consists of a mature TM
o 40
x
E
20
to
Amount ofAntibody (pglml)
Figure 4 . Anti-VLA01 and antiVLA-4 antibodies inhibit CD4 cell
proliferation induced by anti-CD3 plus CS1 peptide . CD4 T cells were
incubated for 30 min with various concentrations of antiVLA01 (4114,
filled circles), antiVLA-4 (8F2,filled squares), antiVLA-5 (2H6, open circles;
and mAb 16, open triangles), or anti-LFA1 (2F12, open squares), and then
plated on culture plates coated with anti-CD3 plus CSl peptide. After
4 d of culture, proliferation was assessed by determination of [3H]thymi-
dine incorporation . The data are expressed as themean of triplicate samples .
Each SD was <15% . The data shown are representative of five separate
experiments .
cell population expressing CD3/TCR, CD4, VLA-4, and
VLA-5 antigens (data not shown) .
As shown in Fig . 5 a, Jurkat cells hardly bound to control
CS1-uncoated plates . Their binding increased >20-fold when
they were plated in microtiter plates coated with CSl-IgG
conjugates . On the other hand, CSI-scrl showed no binding
activity, suggesting that the binding o£Jurkat cells to CS1
peptides is specific. WhenJurkat cells were preincubated with
a saturatingamount of anti-4134, binding ofCSl coated plates
was almost completely abolished (Fig. 5 b) . Likewise, anti-
Figure 5 .
￿
VLA-4 mediates Jurkat cell binding to CSl-coated plates . (a)
Jurkat cells specifically adhere to plates coated with CSl peptide . Adhe-
sion assays were performed as described in Materials and Methods using
microtiter plates coatedwith CSl or CSl-scrl peptide at theindicated doses .
Binding is expressed as counts per minute by [3H]thymidine incorporated
into bound cells . (b) AntiVLA,31 and antiVLA-4 antibodies block Jurkat
cell binding to a CSl-coated plate. Jurkat cells were incubated with indi-
cated antibodies (10 t~g/ml) for 30 min before the adhesion assays using
microtiter plates coated with CSl peptide (2 .5 nmol/ml) . Background
binding to CS1-uncoated plates was <1,000 cpm .
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8F2 (antiVLA4) inhibited this binding, although its effect
was partial compared with anti-4114 . In contrast, neither anti-
2H6 nor mAb 16 (Fig. 5 b), nor other antiVLA antibodies
(data not shown), showed inhibitory activity. Thus, only anti-
4B4 and anti-8F2 inhibited binding, suggesting that the
binding of Jurkat cells to CSl is mediated by VLA-4 .
Activity ofCSI Peptidesfor Promoting CD4 Cell Proliferation
Parallels Their T Cell Adhesion-Promoting Activity . To further
determine whether the adhesion activity of various CSI-related
peptides for Jurkat cells and their activity in promoting CD4
cell proliferation were correlated, we compared Jurkat T cell
attachment activity and CD4 cell stimulation activity between
CSl and its peptide homologues listed in Fig. 1 . As shown
in Fig . 6 a, the original CS1 peptide had the strongest Jurkat
cell binding activity, followed by CSI-D, and then CS1-A .
This order of adhesive activity exactly matched the results
seen using amelanoma cell line (Komoriya et al ., manuscript
in preparation) . Furthermore, this was also the same order
seen in their activity to stimulate T cells, with CS1 being
the strongest, CS1-D second, and CSI-A third (Fig. 6 b) .
CS1-B and CS1-scrl had neither adhesion nor activation ac-
tivities. These results, taken together with the antibody in-
hibition studies, strongly suggest that the binding of CS1
peptide by CD4 cells viaVLA-4 is required for their prolifer-
ation in our system . Moreover, our results suggest that the
EILDVPST sequence in the CS1 domain appears to be
significantly involved in both the T cell adhesion and activa-
tion processes .
CD4 Cell Proliferation Inducedby Anti-CD3 and NativePlasma
FN Is Dependent on Both VLA-4 and VLA-5. Based on
the above findings, we concluded that the CSl alternatively
spliced domain ofFN, through its interaction with VLA-4,
provides a signal synergistic with anti-CD3 to promoteCD4
cell proliferation in this serum-free culture system . Next, we
determined whether the CS1 domain within the native FN
molecule could act in a fashion similar to these synthetic
CSl peptides in inducing CD4 cell activation . For this
Figure 6 .
￿
The activity of CSl
in promotingCD4 cell prolifera-
tion parallels its strength of T cell
adhesion promoting activity. (a)
Comparison ofactivity ofvarious
CSl peptides to promote Jurkat
cell adhesion . Adhesion assays
were performed using microtiter
plates coated with CS1 or its
related peptides at a concentration
of 2.5 nmol/ml. (b) Comparison
of the activity ofvarious CS1 pep-
tides to promote CD3-dependent
CD4 cell proliferation .CD4 cells
were cultured on plates coated
with various amounts of CS1 and
its related peptides ; CSl (open
squares), CSI-D (filled squares), CS1-A (open circles), CSl-B (filled circles),
CSl-scrl (open triangles) . After 4 d of culture, proliferation was assessed
by determination of [3H]thymidine incorporation. The data are expressed
as the mean of triplicate samples. Each SD was <15% . The data shown
are representative of three separate experiments .purpose, we performed theCD4 cell proliferation assay using
purified plasma FN in place of CS1 conjugates as described
previously (9) .
PlasmaFN includes both theCS1 domain, whose receptor
was shown to be VLA-4, as well as a cell binding domain
that contains the RGDS sequence, which is recognized by
VLA-5 . Our previous studies (9) demonstrated that anti-
VLA01 (4134), as well as antiVLA-5 (mAb 16), almost com-
pletely inhibited CD4 cell proliferation induced by anti-CD3
plus plasma FN . In this study, we examined CD4 cells from
eight different donors to determine which FN receptors were
used in the CD4 cell proliferation induced by intact plasma
FN . In each of the eight donors examined, CD4 cell prolifer-
ation could be inhibited >95% by adding either antiVLA01
or anti-VLA-5 (mAb 16 or 2H6) antibodies to the culture
medium at a concentration of 0.4Ag/ml or more. This sup-
ported the previous data that CD4 cells predominantly use
VLA-5 as FN receptor in anti-CD3 plus FN-induced activa-
tion . Fig . 7 shows representative data obtained from two
donors. Although the inhibition by antiVLA5 was predom-
inant, it should also be noted that antiVLA4 (81`2) exhibited
a significant but partial inhibitory effect . The inhibition of
VLA4-mediated proliferation by 8F2 ranged from 10 to40%
(mean 33%) in eight donors. On the other hand, anti-LFA1
(21`12) antibody had no effect, confirming the specificity of
the inhibitionby anti-81`2 . Separate experiments showed that
soluble CS1 peptide could also partially inhibit CD4 cell ac-
tivation in response to intact plasmaFN plus anti-CD3 (data
not shown) . These studies suggest that T cell proliferation
induced by native FN plus anti-CD3 is dependent on both
VLA-4 and VLA-5, although the VLA-5 receptor appears to
predominate.
Intetaction ofVLA-5 withRGDSMay Be Requiredfor VLA-
4/CSI-mediated CD4 Cell Proliferation Induced by Anti-CD3
Plus Plasma Fibronectin . Although antiVLA-4 inhibitedCD4
cell proliferation by 10-40% in our system, nearly complete
inhibition can be achieved by antiVLA5 . It is unlikely, how-
Figure 7 . CD4 cell prolifera-
tion induced by anti-CD3 plus na-
tive plasma FN is dependent on
both VLA-4 and VLA-5, but this
activation does not occur after the
VLA-5/RGDS interaction is
blocked by either antiVLA5 or
mAb 333 . CD4 cells were pre-
incubated with the indicated
amount of various antibodies for
30 min : antiVLA01 (4134 ; open
circles), antiVLA-4 (81`2, filled'cir-
cles), anti-VLA5 (2H6, open squaw,
and mAb 16, filled squares), and
anti-LFAI (21`12, open triangles),
and thencultured on plates coated
with anti-CD3 (0.1,ug/ml) plus plasma FN (10,ug/ml) . mAb 333 (filled
triangles) was added to the culture plates 30 min before addition of CD4
cells. After culturing for 4 d, proliferation was assessed by determination
of [3H]thymidine incorporation . The data are expressed as the mean of
triplicate samples. Each SD was <15% . Representative data from two (a,
donor 1; and b, donor 2) of eight -donors are shown .
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ever, that antiVLA-5 crossreacts with VLA4 or that pertur-
bation of the VLA-5 molecule by antiVLA-5 antibody
transmits a negative signal to theVLA4/CSI pathway, since
antiVLA5 had no effect on CD4 cell proliferation induced
by the CS1 peptide (Fig. 5) . Therefore, the above findings
imply that the VLA-5 receptor may play a role in facilitating
the interaction of the CS1 domain in native FN with the
VLA-4 receptor. Our previous observation that addition of
RGDS peptides almost completely blocks CD4 cell prolifer-
ation induced by anti-CD3 plus plasma FN (9) supports the
notion that interruption of interaction of the VLA-5 with
the RGDS-containing domain results in an inability of the
VLA4/CSI complex to function . To further clarify the above
points, we used a unique anti-FN antibody, mAb 333 . This
antibody binds close to central cell binding domain, and thus,
interferes with binding of the RGDS domain to the VLA-5
receptor (20) . Moreover, it has been recently shown that mAb
333 does not block adhesion between the CS1 region of na-
tive FN and VLA-4 (12). Therefore, we tested whether the
CS1 domain could induceCD4 cell activation after the inter-
action betweenRGDS sites and VLA5 was blockedbymAb
333 . As shown in Fig. 7, virtually no T cell proliferation
was observedwhen mAb 333 was added to the culture system
at a concentration of 2 ug/ml or more. This result strongly
suggests that the interaction of VLA-4 and CS1 does not
operate efficiently when the RGDS domain of native plasma
FN is blocked. Thus, the interaction ofVLA5 with RGDS
may be required to facilitate the interaction betweenCS1 and
theVLA-4 receptor forCD4 cell proliferation, or the VLA-4
and VLA-5 receptors may undergo a partial cooperativity in
their interaction with FN .
Discussion
Using syntheticCS1 peptide, we have shown that this al-
ternatively spliced domain ofFN promotes not only T cell
adhesion, but also CD4 cell proliferation when combined
with anti-CD3 in a serum-freeculture system . Moreover, these
two different biologic processes, i.e., adhesion and prolifera-
tion, were shown to be mediated by theVLA-4 receptor. In
addition, our study showed that the CD4 cell proliferation
induced by anti-CD3 plus native plasma FN is dependent
upon both VLA4 and VLA5, although the latter is pre-
dominant . These results might help explain the preferential
responsiveness of CD4+CD45RA - CD29+(CD29h'sh) cells
to soluble antigens (4, 22), since this CD4 cell subset ex-
presses high levels ofboth theVLA-4 andVLA5 FN receptors
(9, 23), which can synergize with the CD3/TCR pathway
during T cell activation .
It is clear that synthetic CS1 peptide provides a potent
costimulus for CD4 cells. However, when the CS1 domain
is located within native plasma FN molecules, theCS1/VLA4
interaction seems to be less active in its ability to generate
an activation signal for CD4 cells than the VLA5/RGDS
interaction . Although CD4 cell proliferation in response to
nativeFN plus anti-CD3 was partially inhibitedbyantiVLA4
antibodies, proliferation was essentially completely inhibited
when the VLA-5/RGDS interaction was blocked by anti-VLA5, RGDS peptide, or mAb 333. Our results suggest
that VLA4-mediated proliferation is dependent upon inter-
action ofVLA-5 with the RGDS domain contained in the
native plasma FN molecule. Hemler et al . (24) have also
reported adhesion data quite similar to our own, obtained
using K562 cell lines transfected with VLAo14 cDNA . Al-
though the transfected K562 cells expressed bothVLA-4 and
VLA-5 in approximately equal levels, their adhesion to intact
plasma FN was almost completely inhibited by antiVLA5,
but not by antiVLA4 . On the other hand, our present data
contrast with previous reports thatVLA4 and -5 can indepen-
dently recognize the CS1 and RGDS domains of native FN,
respectively (10, 12) . Mould et al . (12) have recently demon-
strated that spreading ofA375-M, ahuman metastatic mela-
noma cell line, could be observed even after the central cell
binding domain (RGDS) was blocked by anti-mAb 333, and
that the residual spreading could be completely inhibited by
either antiVLA#1 or antiVLA-4 . These adhesion data indi-
cate that the CS1 domain in native FN is active and can pro-
mote cell adhesion independently from the RGDS domain.
The apparent discordancebetween our results and theprevious
binding studies could be due to methodological differences
(in proliferation and adhesion assays), or due to the different
cell types used (peripheral CD4 cells vs. adherent cell lines) .
Theremay be several possible explanations for the apparent
requirement for VLA5/RGDS interaction in VLA-4/CS1-
dependent activation ofCD4 cells by anti-CD3 plus native
FN. First, the binding affinity ofVLA4 on restingCD4 cells
for the CS1 domain might be quite low (presumably lower
than the same receptor on melanoma cells), so it would not
be able to bind FN . According to this hypothesis, the VLA-
5/RGDS interaction might facilitate the binding ofVLA-4
simply by stabilizing the CS1/VLA-4 interaction, or by ac-
tivatingVLA-4 to a high-avidity state . A second possibility
is that the binding ofVLA5 changes the conformation of
theFN molecule, permitting more effective binding ofVLA4
to the CS1 site. A third possibility is that the amount of CS1
domain contained in plasma FN may not be enough to acti-
vate CD4 cells without assistance from the RGDS/VLA5
interaction. PlasmaFN is composed oftwo polypeptide chains
(25) covalently associated to form a dimer. Both chains have
central cell binding domains containing RGDS sites, so each
plasma FN molecule has two binding sites for VLA-5 . In
contrast, only one chain has the IIICS containing the CS1
sequence . Moreover, the CS1 sequence can be spliced out of
some FN molecules. Therefore, the molar ratio of CS1 and
RGDS inhuman plasmaFN is <1:2 . This lower ligand den-
sity may lead to the inability of the CS1/VLA4 interaction
to activateCD4 cells by itself. To increase the density ofCS1,
FN was coated onto the plates at a higher concentration (up
to 100 ttg/ml) . However, mAb 333 was still able to com-
pletely abolish CD4 cell proliferation (data not shown) . Al-
though we cannot exactly compare the number of CS1 se-
quences contained in plasma FN with those in the synthetic
peptide-IgG conjugates we used, the latter may be better able
to trigger VLA-4-mediated activation because of their com-
paratively greater ligand density. Whatever the mechanism,
it is clear that peripheral CD4 cells preferentially use VLA-5
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as functional FN receptor in ourCD4 cell activation system .
This finding should be stressed, considering the fact that
VLA-4 is expressed more abundantly than VLA-5 on periph-
eral CD4 cells (7) .
The predominant usage of VLA-5 by CD4 cells does not
necessarily negate the significance of VLA-4 in T cell func-
tion . At present, we can only use plasma and not cellular
FN as a source of FN . Since a cell type-specific difference
in the CS1 expression has been demonstrated (26), it may
be possible that the CS1 domain of FN is more abundantly
expressed in tissue matrix, inflammatory regions, or on the
surface ofAPC. If such were the case, FN might have a higher
avidity for binding T cells bearing VLA4 (11) . Furthermore,
it has been recently demonstrated thatVLA4 is also a receptor
for VCAM-1, which is a cell surface adhesion molecule in
the Ig gene super family (27) . VCAM-1 can be induced on
lymphokine-activated endothelial cells (28) . Using K562 cell
lines transfected withVLAcx4cDNA, Elices et al . (27) have
shown that VCAM-1 interacts with VLA-4 at a site distinct
from the CS1 binding site . Most recently, Komoriya et al .
(manuscript in preparation) have narrowed down the mini-
mum active site for melanoma cell adhesion to CS1 to a tripep-
tide, Leu-AspVal (LDV) . Most interestingly, the LDV se-
quence can be found in VCAM-1 (28) . If this sequence is
also active in VCAM-1 as in FN, the interaction ofVLA4-
bearingT cells with VCAM-1 on activated endothelial cells
could result in T cell activation . Although further studies
are necessary to determine whether the LDV sequence in
VCAM-1 plays a role in CD4 cell activation, the above result
leads us to speculate that VLA4 may play a key role in inflam-
matory sites through interactions with activated endothelium
or FN deposited within these sites (27) .
Evidence that adhesion molecules play an important role
in T cell immune function has been accumulating (29) . The
primary pathway for clonal expansion of T cells occurs by
means of antigen recognition by the CD3/TCR complex .
However, a number of cell surface adhesion molecules, in-
cluding CD2/LFA-3 (30-32), CD4/MHC class II (33, 34),
CD8/MHC class I (35), and LFA-1/ICAM-1(36), have been
shown to synergize with theCD3/TCR complex in this an-
tigenic response . Cell-cell contact may be an important con-
sequence of these adhesion events ; however, these accessory
interactions also appear to trigger intracellular signals that
modify antigen-driven proliferation via the CD3/TCR com-
plex (36, 37) . In addition to cell-cell interactions, cell-extra-
cellular matrix protein contacts have attracted increasing at-
tention by virtue of their costimulatory effect upon lymphocyte
activation (9, 38, 39) . Dang et al . (38) have recentlydemon-
strated that collagen provides a costimulatory signal with the
CD3 pathway in promotingCD4 cell proliferation . This effect
is mediated by VLA-3 and CD26 (1F7) . Moreover, laminin
has also beenshown to induce C133-dependent T cell prolifer-
ation via interaction with VLA-6 (39) . Thus, a costimula-
tory effect on lymphocyte activation may be a general char-
acteristic of extracellular matrix proteins .
Little is known about the mechanism of comitogenic signals
induced by extracellular matrix proteins. It is also still un-
clearwhy mammalian cells have multiple specificities in theirligand-receptor interactions, such as FN/VLA4 vs. FN/
VLA5 andVLA4/FN vs . VLA4/VCAM-1 . Are there any
differences in the signal transduction and biological conse-
quences caused by stimulation of these various ligand-receptor
combinations? Engagement ofthese receptorsby their respec-
tive ligands generates intracellular signals that lead ultimately
to the biological expression of distinct functional programs
of eachTcell subset . TheTcell proliferation system described
in our study is a suitable model for continued study of the
intracellular signals delivered to T cells by extracellular ma-
trix proteins.
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